Figure and Table | Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab

Table 1. MTX-HOPE Protocol.

Agent	Dose/day	Route	Days of administration
Methotrexate (MTX)	20 mg	po	1
Hydrocortisone (HC)	100 mg	div (15min)	2
Vincristine (VCR)	1 mg	div (15min)	2
Sobuzoxane (MST-16)	400 mg	po	3, 4
Etoposide (ETP)	25 mg	po	3, 4